Detail akcie Bioceltix Br online

Business Summary: Bioceltix SA is a Poland-based biopharmaceutical company, which operates in the field of veterinary medicine. The Company deal with the development of candidates for veterinary medicinal products based on the immunomodulatory properties of mesenchymal stem cells used as the active substance of the drug. Entity's products are intended for the treatment of companion animals. The Company carry out research and development works, which enable clinical trials and full registration of medicinal products in the European Medicines Agency, as is the case with medicines and drugs administered to humans.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Bioceltix SA revenues was not reported. Net loss remained flat at PLN11.9M. Net income also reflects External Services decrease of 32% to PLN5.4M (expense), Property & Other Taxes decrease of 86% to PLN121K (expense), Interest Income - Non-Bank increase of 38% to PLN222K (income), offset by Grant decrease of 61% to PLN880K (income), Wages and Salaries increase of 39% to PLN4.1M (expense).